NCT05846971

Clinical Utility of Methylation-based Prognostic Assay for Barrett's Esophagus

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 100 (estimated)
• Sponsor: Capsulomics, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions when presented with different clinical and prognostic assay information.

Detailed description

Capsulomics has developed a prognostic assay for patients with diagnosed Barrett's esophagus (BE). This study will measure how gastroenterologists make surveillance and treatment management decisions for virtual patient cases when presented with different clinical and prognostic assay information. The data from this study will be published in a peer-review scientific journal.

Conditions

• Barrett Esophagus
• Esophageal Cancer

Interventions

Type	Name	Description
OTHER	Educational materials on validated methylation assay	Educational materials include overall information on the assay including what the test does, how to use the test and report, and performance metrics on the test.

Timeline

• Start date: 2021-01-26
• Primary completion: 2023-12-31
• Completion: 2023-12-31
• First posted: 2023-05-06
• Last updated: 2023-05-06

Locations

1 site across 1 country: United States